Alzheimer drug trial stops after cognitive scores decline

07/25/2013 |

Researchers at Baylor College of Medicine terminated a clinical trial testing the drug semagacestat for the treatment of Alzheimer's disease after patients in the treatment and placebo groups showed comparably worsening cognitive scores. The team's study also reported in the New England Journal of Medicine that semagacestat was linked to increased adverse events, including skin cancer and infection.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Fort Worth, TX
Senior Scientist - Cell Engineering Group
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC